Route choice
Transdermal vs oral estrogen: what actually changes
A focused evidence page on route choice when women are comparing symptom relief, clot-risk framing, and what current guidance actually uses to choose.
Tier 1 governed claim
When systemic estrogen is appropriate and clot risk matters, transdermal delivery is often preferred because pooled comparative data suggest lower VTE risk than oral estrogen.
Governed claim cp_menopause_transdermal_lower_vte_signal_v1
Why route choice matters
Women often hear 'HRT' as if it were one thing. In reality, route changes both the prescribing conversation and the way risk gets framed, especially when clot risk or first-pass liver effects matter.
What the evidence comparison is really about
The most useful comparison is not whether one route sounds more natural. It is whether one route changes relative clot-risk signal, convenience, or tolerance without giving up the symptom relief you are trying to preserve.
What to decide with a clinician
A high-quality route decision should include clotting history, migraine, blood pressure, uterine protection needs, skin tolerance, and whether the route changes the overall fit of systemic therapy for you.
Next step
Reading the evidence is useful. Matching it to your history is the real decision.
The assessment narrows symptom pattern, contraindications, and treatment preferences so a clinician can explain which option actually fits you, not just which option sounds best on a generic page.